-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

Benzinga·03/11/2025 13:08:34
Listen to the news
Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.